AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Company profile
Ticker
ABBV, ABBV-MM
Exchange
Website
CEO
Richard Gonzalez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...
IRS number
320375147
ABBV stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
8-K
Other Events
26 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
FWP
Free writing prospectus
22 Feb 24
S-8
Registration of securities for employees
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
Transcripts
ABBV
Earnings call transcript
2023 Q4
2 Feb 24
ABBV
Earnings call transcript
2023 Q3
27 Oct 23
ABBV
Earnings call transcript
2023 Q2
27 Jul 23
ABBV
Earnings call transcript
2023 Q1
27 Apr 23
ABBV
Earnings call transcript
2022 Q4
9 Feb 23
ABBV
Earnings call transcript
2022 Q3
28 Oct 22
ABBV
Earnings call transcript
2022 Q2
29 Jul 22
ABBV
Earnings call transcript
2022 Q1
29 Apr 22
ABBV
Earnings call transcript
2021 Q4
2 Feb 22
ABBV
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
144
Notice of proposed sale of securities
18 Mar 24
4
TIMOTHY J. RICHMOND
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Scott T Reents
1 Mar 24
4
Kevin K Buckbee
1 Mar 24
4
Robert A. Michael
1 Mar 24
4
Perry C Siatis
1 Mar 24
4
Jeffrey Ryan Stewart
1 Mar 24
4
AZITA SALEKI-GERHARDT
1 Mar 24
4
TIMOTHY J. RICHMOND
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
49.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2718 |
Opened positions | 273 |
Closed positions | 515 |
Increased positions | 965 |
Reduced positions | 1180 |
13F shares | Current |
---|---|
Total value | 127.78 tn |
Total shares | 872.48 mm |
Total puts | 4.96 mm |
Total calls | 6.98 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 160.40 mm | $24.86 tn |
STT State Street | 78.20 mm | $12.12 tn |
JPM JPMorgan Chase & Co. | 51.82 mm | $8.03 tn |
Capital International Investors | 44.99 mm | $6.97 tn |
MS Morgan Stanley | 34.05 mm | $5.28 tn |
Capital Research Global Investors | 30.30 mm | $4.70 tn |
Charles Schwab Investment Management | 24.45 mm | $3.77 tn |
BK Bank Of New York Mellon | 22.10 mm | $3.43 tn |
NTRS Northern Trust | 20.94 mm | $3.24 tn |
LGEN Legal & General | 15.21 mm | $2.36 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 177.71 | 20,127 | 3.58 mm | 13,837 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 176.35 | 9,853 | 1.74 mm | 33,964 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 177.71 | 30,288 | 5.38 mm | 43,817 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 176.4 | 15,412 | 2.72 mm | 74,105 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Option exercise | Acquire M | No | No | 61.36 | 45,700 | 2.80 mm | 89,517 |
1 Mar 24 | Timothy J. Richmond | Option Common Stock | Option exercise | Dispose M | No | No | 61.36 | 45,700 | 2.80 mm | 0 |
29 Feb 24 | Kevin K Buckbee | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 176.65 | 5,144 | 908.69 k | 6,983 |
29 Feb 24 | Robert A. Michael | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 176.46 | 47,319 | 8.35 mm | 98,645 |
29 Feb 24 | Robert A. Michael | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 176.44 | 21,560 | 3.80 mm | 145,964 |
29 Feb 24 | Robert A. Michael | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 54.86 | 10,140 | 556.28 k | 167,524 |
News
10 Health Care Stocks Whale Activity In Today's Session
18 Mar 24
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
18 Mar 24
Decoding AbbVie's Options Activity: What's the Big Picture?
14 Mar 24
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
11 Mar 24
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
8 Mar 24
Press releases
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
7 Mar 24
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
6 Mar 24
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
5 Mar 24
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
28 Feb 24
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 24